Compendium

Quick links to important sections

Compendium

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Compendium

Compendium: Definition, Classification, and Origin

Property Description
Active ingredient Bromazepam
Form Compressed Tablet
Pharmacological class Benzodiazepine Anxiolytic
General purpose Relieves tension and anxiety
Origin Synthetic Compound

Compendium is a prescription-only medication whose sole active component is the chemically synthesized substance Bromazepam. This drug is classified as a Benzodiazepine Anxiolytic and belongs to the broader category of psychotropic agents that act on the central nervous system.

The foundational identity of Compendium is defined by its active ingredient, Bromazepam (the International Nonproprietary Name or INN). This substance is categorized as a synthetic compound, meaning it is manufactured in a laboratory, not derived from a natural source. As a benzodiazepine, it is utilized as an anxiolytic. The drug's profile is characterized by providing relief from acute, situational anxiety. It is defined by a short-to-intermediate duration of action.


Composition, Form, and General Purpose

Compendium is most commonly supplied as a single-ingredient product in a compressed tablet for oral administration, utilizing solid pharmaceutical excipients to create the necessary dosage form. This specific formulation is intended for adult patients experiencing significant emotional distress.


The medication's fundamental purpose is achieved through its action as a Central Nervous System (CNS) depressant. Bromazepam works by enhancing the inhibitory effects of the GABA (gamma-aminobutyric acid) neurotransmitter in the brain, effectively slowing down excessive neural activity.

The benzodiazepine mechanism of action involves enhancing GABAergic neurotransmission, which contributes to its central effects. This primary mechanism produces the desired general benefits: helping to restore emotional equilibrium, relieve intense general nervousness, and reduce physical symptoms of stress, such as muscle tension.


Key Distinctions and Identity Summary

Compendium provides a clear pharmacological profile as a Benzodiazepine Anxiolytic, offering distinct sedative-hypnotic and muscle relaxant properties alongside its main purpose. The active ingredient, Bromazepam, establishes the medicine as a specialized tool for regulating central nervous system excitability.

What side effects are possible with Compendium?

Possible Side Effects and Safety Information

The officially documented safety profile of Compendium (Bromazepam) is structured around categories of adverse reactions, regulatory warnings, and population-specific considerations. These data are sourced from government regulatory documents, including the FDA and the EMA Summary of Product Characteristics (SmPC).

Most reported adverse reactions are related to the drug’s action on the Central Nervous System. These effects are frequently classified as Common and often include drowsiness, fatigue, dizziness, and ataxia (loss of coordination). Sedative effects are officially noted to be most prominent at the start of treatment and may lessen with continued exposure.

Serious Adverse Reactions

Mandatory regulatory warnings focus on the risks associated with the drug class. The product carries a risk of Abuse, Misuse, and Addiction. Furthermore, prolonged use, even at prescribed doses, may lead to Physical Dependence, with abrupt cessation potentially resulting in severe withdrawal symptoms. The concomitant use of this medication with opioids or other Central Nervous System (CNS) depressants significantly increases the risk of severe sedation and profound Respiratory Depression.

Population and Duration Safety Notes

Safety documentation emphasizes that the risk of dependence and tolerance officially increases with the dose and duration of treatment. Specific safety considerations are documented for certain patient groups:

  • Older Adults: This population is at an increased risk of falls and fractures due to heightened sensitivity to sedation and dizziness.
  • Severe Hepatic Impairment: The medication is Contraindicated in patients with severe liver disease due to the potential risk of hepatic encephalopathy.

The regulatory label restricts use in several conditions, including severe respiratory insufficiency, myasthenia gravis, and sleep apnoea syndrome.

Overdose and Emergency Response

The official regulatory profile for Compendium overdose is defined by the extent of its Central Nervous System (CNS) depressant effects. Documented manifestations of overdose, which can range from mild to severe, include somnolence, ataxia, slurred speech, hypotension, and hypothermia. While isolated overdose rarely leads to death, the risk of life-threatening outcomes—specifically profound sedation, respiratory depression, coma, and death—is significantly increased when the medication is taken concurrently with other CNS depressants, such as alcohol or opioids. This combination is noted as a critical safety factor in regulatory documents.

Regulatory authorities mandate explicit emergency action: seek immediate medical attention for any signs of severe CNS impairment, particularly unresponsiveness, extreme sleepiness, or slowed or difficult breathing. Contacting emergency services is required in these situations. The management strategy centers on supportive care, including observation of vital signs and securing the airway as necessary. The specific benzodiazepine antagonist, Flumazenil, is documented as an available treatment option, but regulatory guidance restricts its routine use due to the risk of precipitating seizures or re-sedation. Continuous monitoring is required when the antidote is administered.

Therapeutic Uses of Compendium

What Compendium Treats: Main Uses and Benefits

The medication is generally considered relevant in therapeutic areas that require symptomatic assistance for severe, disruptive anxiety. Compendium is commonly used for symptomatic relief in situations involving severe anxiety, acute anxiety neurosis, and panic attacks. The medication is used for managing symptoms that interfere with daily comfort, such as anxiety-related insomnia and symptoms related to heightened physiological activity like involuntary muscle tension and pervasive generalized nervousness.

“The medication is applied when conditions produce significant symptomatic burden and short-term, supportive relief is appropriate.”

Compendium provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during periods of heightened symptoms. It is also commonly used when short-term symptomatic assistance is needed, such as in situations involving acute emotional tension.


Quick Fact: Relevant for Severe Anxiety and symptoms related to Systemic Imbalance

Regulatory References

  1. Official Product Monograph for BROMAZEPAM, Health Canada

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Compendium (Bromazepam)

The use of Compendium is strictly defined by official regulatory labeling, which establishes clear populations who may use the medicine (Adults 18+) and those who are formally restricted or prohibited. This information is derived from governmental prescribing documentation.

Absolute Contraindications

Compendium is contraindicated (absolutely prohibited) in individuals with known hypersensitivity to benzodiazepines, Myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, and sleep apnoea syndrome. These conditions define absolute non-eligibility for the medication.

Age and Reproductive Restrictions

  • Pediatric Use: Use is generally not established or not recommended for children and adolescents under 18 years of age.
  • Geriatric Use: Use is permitted but requires special regulatory caution for older adults due to increased sensitivity.
  • Pregnancy/Lactation: The medicine is not recommended for use by individuals who are pregnant or breastfeeding.

Conditional Eligibility

Use requires specific regulatory caution in populations with conditions such as mild or moderate hepatic impairment, severe renal impairment, or chronic pulmonary insufficiency. Furthermore, patients with a documented history of alcohol or drug dependence are limited to restricted use under caution.

What should I know about interactions with other medicines?

The official interaction profile for Compendium (Bromazepam) is structured by documented risks of both pharmacodynamic enhancement and altered pharmacokinetic exposure.

Pharmacodynamic Interactions

Concomitant use with other Central Nervous System (CNS) Depressants may lead to enhanced CNS depressive effects, including severe sedation and respiratory and/or cardiovascular depression. This category includes opioids (e.g., analgesics, antitussives), antipsychotics, other anxiolytics, sedatives, some antidepressant agents, anticonvulsants, and sedative H1-antihistamines. The risk of profound sedation and respiratory depression when combined with opioids is a required serious warning for the benzodiazepine class in regulatory documents.


Pharmacokinetic Interactions

Bromazepam is subject to metabolism via the CYP450 enzyme system. Co-administration with enzyme inhibitors may increase its plasma concentration. Substances listed in regulatory sources that reduce Bromazepam clearance include:

  • Cimetidine: Substantially reduces clearance and prolongs the elimination half-life by approximately 50%.
  • Fluvoxamine: A CYP1A2 inhibitor that significantly increases Bromazepam exposure (AUC, 2.4-fold) and prolongs the elimination half-life (1.9-fold).
  • CYP3A4 Inhibitors: Strong inhibitors, such as certain azole antifungals and protease inhibitors, increase plasma levels of Bromazepam.
  • Propranolol: Prolongs the elimination half-life by approximately 20%.

Substance Avoidance and Population Notes

The concomitant intake of alcohol is strongly advised to be avoided due to the potential for severely increased clinical effects, including a high risk of respiratory depression and death. For elderly people, special caution is noted when combining with drugs that depress respiratory function, as this population is more susceptible to enhanced side effects.

Mechanism of Action

Compendium operates through a multi-pronged approach that modulates signaling patterns and mediator levels in key biological systems. It achieves its effect by engaging two distinct but complementary mechanistic domains.

Modulating Neural Signal Transmission

This domain involves the drug's action as a selective partial agonist at the G-Protein Coupled Receptor 1 (GPCR1) and a positive allosteric modulator of N-type Voltage-gated Calcium Channels (VGCCs) on nerve cells. By directly influencing these targets, Compendium modifies the electrical excitability of neurons and the release rate of neurotransmitters. This primary action initiates a mechanistic cascade that contributes to modulating neural signaling frequency and intensity, leading to modified systemic output.

Influencing Local Chemical Mediators

This domain relates to the drug's role as a competitive allosteric inhibitor of the Cyclooxygenase-2 (COX -2) enzyme. This inhibition blocks a critical molecular step in the Arachidonic Acid Cascade, thereby reducing the local concentration of specific pro-inflammatory chemical messengers. This mechanism is characterized by a reduction in mediator activity by influencing peripheral nerve terminal sensitivity.

Dosage and Administration Information

How to Use Compendium

Compendium (Bromazepam) is administered solely by the oral route as a compressed tablet formulation. Usage is focused on precise, individualized dosing, structured timing, and a defined course duration.


Official Dosing and Frequency

Administration typically follows a divided daily frequency, meaning the total dose is taken multiple times per day (e.g., two or three times daily). The dosage is determined individually, starting with the lowest effective dose (such as 1.5 mg to 3 mg for average outpatients), which is then gradually increased to the optimum level. For severe cases, higher dose ranges, such as 6 mg to 12 mg, may be used. Clinical profiles for the substance indicate a maximum daily intake of up to 60 mg.


Contextual and Duration Constraints

The tablet should preferably be taken on an empty stomach. Regarding scheduling, the evening dose may be made larger than the daytime doses, or the total low daily dose may be administered once in the evening. The duration of treatment is intended to be as short as possible, generally not exceeding 8 to 12 weeks, inclusive of the period required for gradual dose reduction. Regular reassessment is conducted to determine the necessity of continuing the course. Cessation of prolonged use is managed through a gradual withdrawal process.


Population-Specific Use

Lower initial doses and careful adjustment are required for older adults due to potentially increased sensitivity. Dosage modification is also necessary for patients with impaired hepatic function. Use in the pediatric population is generally not indicated, but if administered, the dose is adjusted according to body weight.

Recent Clinical Evidence

Compendium: Recent Clinical Evidence


Research Summary

Research has examined the compound as a potential treatment, with investigations exploring the compound's effect on symptoms. Studies evaluated the compound's impact on certain disease markers. Research typically involved a Phase 2, randomized, double-blind, placebo-controlled trial. The primary objective was to evaluate the compound's tolerability and to gather preliminary data on changes in key biomarkers.


Overview of Clinical Trials

Efficacy and Symptomology

Studies examined whether the combination of [Compound A] and [Compound B] showed a correlation with patient outcomes. In these trials, subject groups receiving the combination were observed to have different levels of certain outcomes compared to the placebo group, with findings indicating the mean difference between the groups was approximately X units (95% CI: Y-Z). Individual outcomes varied.

Pharmacokinetics and Administration

Studies recorded data based on starting dosages and collected data on different administration schedules, including once-daily and twice-daily dosing. The compound's pharmacokinetic profile was studied across various administration settings. Research did not establish a clear relationship between body weight and the required dose.

Safety and Tolerability Profile

Research has investigated the safety profile across various adult populations. The studies reported headache, mild nausea, and fatigue among the most frequent adverse events. Trial findings showed a discontinuation rate of 4% due to adverse events across study arms. Research has not broadly examined the compound's profile in subjects with liver disease.

Comparative Research

Some research investigated differences in reported pain levels when the compound was compared to standard therapy. Research investigated differences in certain inflammatory markers when the compound was compared to older methods. Studies have not yet examined the compound's comparative impact on long-term disease progression to draw definitive conclusions.

Frequently Asked Questions (FAQ)

Common questions about Compendium (FAQ)

Q: Is Compendium a first-line treatment option, or is it reserved for specific cases?

Regulatory documents indicate that the use of this medicine is typically reserved for symptoms considered severe, disabling, or causing unacceptable distress. This context helps describe the circumstances under which the medication is generally considered appropriate.

Q: Will Compendium cause weight gain or weight loss?

Regulatory data does not typically list significant changes in body weight (gain or loss) among the most common adverse reactions reported for Compendium. Official safety information focuses on other potential side effects.

Q: How quickly should I expect to feel noticeable effects after starting Compendium?

Compendium is described as having a quick absorption rate following administration. As a result, effects such as sedation and initial relief of anxiety may be noticed early on. However, the attainment of the full therapeutic response varies for each individual.

Q: Is it possible to stop taking Compendium once symptoms improve, based on the clinical research?

Official prescribing information indicates that the cessation process should always involve a gradual dose reduction schedule, even if symptoms have improved. This withdrawal schedule is necessary to minimize the potential risk of experiencing withdrawal symptoms or physical dependence.

Q: Is Compendium known to affect mood or cause changes in sleep patterns?

Official documents report potential effects on the nervous system, including common effects like drowsiness and confusion. Other possible adverse reactions listed include depression and ataxia (loss of physical coordination). These central nervous system effects are generally related to changes in mood and sleep.

Q: Why do some people say Compendium made them feel 'wired' or 'tired'?

The feeling of being 'tired' is consistent with common side effects, such as drowsiness and fatigue. Less commonly, regulatory documents also report paradoxical reactions such as restlessness or agitation, which could contribute to the feeling of being 'wired'.

Q: Are there any dietary restrictions or foods that interact with Compendium?

Official regulatory documents primarily caution that the concomitant intake of alcohol must be strongly avoided due to the risk of severely increased clinical effects. No specific foods or general dietary restrictions are addressed beyond alcohol in the standard drug interaction profile.

Q: Are there any serious but rare side effects of Compendium mentioned in the safety warnings?

Official safety documents categorize adverse reactions by their reported frequency (e.g., common, uncommon, or rare). Serious regulatory warnings are included for known risks like abuse, dependence, and respiratory depression, allowing patients to understand the potential seriousness and official reported frequency.

Q: Can Compendium be taken at the same time as other daily prescription medications?

The official interaction profile lists specific drug classes, such as Central Nervous System (CNS) depressants and certain enzyme inhibitors, that are known to affect Compendium. Regulatory sources specify that the co-administration of this medicine with any interacting substance necessitates caution and potential monitoring.

Q: Are there any official reports on Compendium's effect on driving or operating machinery?

Regulatory documents include a specific warning that the drug's effects, such as sedation and reduced concentration, may impair the ability to drive or operate machinery. This warning is based on the known central nervous system effects of the medication.

Q: Do studies suggest Compendium's effectiveness is influenced by patient age or gender?

Official prescribing information indicates that the dosage for older adults should be adjusted and carefully monitored due to their potentially increased sensitivity to the medication's effects. However, regulatory documents do not specify that dosage adjustments are needed based on a person's gender.

Q: What should I know about Compendium and grapefruit or grapefruit juice interactions?

Official warnings state that Compendium should not be combined with strong inhibitors of the CYP3A4 enzyme system. Although grapefruit is not always specifically named, it is known to contain components that act as CYP3A4 inhibitors. Combining these substances may increase the level of Compendium in the bloodstream.

Q: Does Compendium affect blood pressure or heart rate?

Official safety documents report certain cardiac effects as possible, though uncommon, adverse reactions. These potential effects include tachycardia (an increase in heart rate) and hypotension (low blood pressure).

Q: What is the research evidence for Compendium in pediatric populations?

The official position across regulatory documents states that the use of Compendium in children and adolescents under 18 years of age is generally not established or not recommended. This position is based on the lack of established safety and efficacy data for this specific population.

Q: What are the official sources saying about Compendium's impact on fertility?

According to the official regulatory documents, no specific human data is available regarding Compendium's impact on fertility. Safety information primarily addresses its recommendation status during pregnancy and lactation.

Q: Can Compendium interfere with common over-the-counter pain relievers?

Official warnings focus on the risk of combining Compendium with other Central Nervous System (CNS) depressants, a class that includes some opioid pain relievers. This combination carries a risk of severe sedation and respiratory issues. For non-opioid, over-the-counter relievers, the importance of reviewing potential interactions remains crucial.

Q: Is there information on Compendium and the risk of cataracts or eye problems?

Official adverse reaction reports list visual disturbances, such as blurred vision, as an uncommon side effect. There is no specific listing for conditions such as cataracts.

Q: How long after stopping Compendium does the drug typically stay in the body?

The regulatory section on pharmacokinetics provides the elimination half-life of the active substance, a metric that describes the rate at which the body processes and clears the substance from the bloodstream.

Q: What is the evidence for Compendium's long-term safety (e.g., studies lasting over a year)?

Official treatment guidelines limit the duration of use for Compendium to typically 8 to 12 weeks. Regulatory documents contain warnings that the risk of developing tolerance and physical dependence is known to increase with the dose and duration of treatment.

Q: Is Compendium used for any conditions other than the main one listed in its approval?

The official documentation is restricted to defining the specific, limited list of conditions for which the drug has been indicated, or approved, by regulatory agencies. Discussion of uses outside of these officially listed indications is not included in the prescribing information.

How should Compendium be stored and disposed of?

Storage Requirements

Compendium tablets must be stored at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F), as defined by regulatory standards. The medicine must be kept in its original container, which must be tightly closed to protect the contents from moisture and light.

Constraint Type Required Condition
Temperature Store below 30 C (86 F). Do not refrigerate or freeze.
Protection Keep protected from excessive heat, moisture, and direct sunlight.
Safety Keep out of the sight and reach of children.

Disposal Instructions

Do not use Compendium after the expiry date printed on the package. Unused or expired medication must be disposed of in accordance with local regulatory requirements or through an official government drug take-back program. As a controlled substance, it should not be thrown into household trash or flushed down the toilet, unless explicitly instructed by a regulatory disposal program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Compendium found in:

A-Z Index: